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Patients with bone cancer metastasis suffer from unbearable pain and bone fractures due to bone remodeling.
This is caused by tumor cells that disturb the bone microenvironment. Here, we have investigated the role of
tumor-secreted sugar-binding protein, i.e., galectin-3, on osteoblast differentiation and report that it downregulates
the expression of osteoblast differentiation markers, e.g., RUNX2, SP7, ALPL, COL1A1, IBSP, and BGLAP, of
treated human fetal osteoblast (hFOB) cells. Co-culturing of hFOB cells with human breast cancer BT-549 and
prostate cancer LNCaP cells harboring galectin-3 has resulted in inhibition of osteoblast differentiation by the
secreted galectin-3 into culture medium. The inhibitory effect of galectin-3 was found to be through its binding to
Notch1 in a sugar-dependent manner that has led to accelerated Notch1 cleavage and activation of Notch
signaling. Taken together, our findings show that soluble galectin-3 in the bone microenvironment niche regulates
bone remodeling through Notch signaling, suggesting a novel bone metastasis therapeutic target.
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Patients with malignant prostate and breast cancer are often afflicted by
bone metastasis [1,2]. The establishment of secondary tumor growth in
the bone affects the bone microenvironment leading to bone
remodeling, i.e., the balance between osteoclast-driven bone resorption
and osteoblast-driven bone deposition [3–5], their differentiation
statuses are essential for their functions [6,7]. It was reported that bone
metastatic cancer cells may affect the differentiation status of both
osteoclasts and osteoblasts through the secretion of cytokines and
growth hormones like PTH-rP, transforming growth factor–β,
fibroblast growth factor (FGF), Wnt, and urokinase-type plasminogen
activator (uPA) to name but few [3–5]. Thus, crosstalk between tumor
cells and the bone microenvironment disrupts normal bone homeosta-
sis, which leads to tumor growth and inappropriate bone remodeling
[3], consequently affecting the quality of life in patients due to pain and
fractures in metastatic lesions [8]. Therefore, understanding the
regulation of bone remodeling is, without a doubt, a clinical priority
and challenge to combat the cancer growth in the bone, since the arsenal
of therapeutic tools available for treatment is thus far limited.
Galectin-3 is a β-galactoside–binding protein comprising 250
amino acid residues and binds to the carbohydrate portion of cellsurface glycoproteins. It is a chimeric gene product composed of three
distinct structural domains: a short NH2-terminal domain containing
a phosphorylation site, a repeated collagen α-like sequence, and a
C-terminal domain containing a single carbohydrate recognition-
binding domain (CRD) composed of 140 amino acids [9].
Galectin-3 was shown to regulate proliferation and apoptosis and
mediates cell-cell and cell–extracellular matrix adhesion for cancer,
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galectin-3 mediates bone metastasis through β-galactoside inter-
actions on the tumor cell surface [11,12]. In addition, we recently
showed that patients with metastases arising from prostate cancer
have a higher serum galectin-3 concentration [13]. Similarly,
circulating galectin-3 levels in the serum of patients with metastatic
breast cancer were higher compared to non-metastatic patients
[14]. Nevertheless, the functional role of galectin-3 in the bone
microenvironment of growing tumors has not yet been explored. On
the basis of the fact that the circulating galectin-3 induces
angiogenesis affecting tumor cell growth in the microenvironment
[15–17], we examined its role in the bone.
Tumor-derived jagged-1, a membrane-associated protein inducing
Notch signaling expression, was reported to be associated with
galectin-3 [18] and causes bone remodeling through cell-to-cell
interaction between cancer cells and osteoclasts or osteoblasts [19]. A
recent study reported that jagged-1 overexpressed in bone metastatic
lesions of patients with breast cancer, implicating the potential role of
Notch signaling in bone metastasis [20]. A preclinical study indicates
that activation of Notch signaling in both osteoclasts and osteoblasts
promotes osteolytic bone metastasis [21]. In addition, it was
previously reported that Deleted in Malignant Brain Tumors 1
protein interacts with galectin-3 and modulates the Notch signaling
pathway [22]. These molecular mechanisms that underlie these
painful and often incurable consequences of tumor metastasis to the
bone have been suggested to be promising new molecular targets for
therapy [3]. Current treatment for bone metastasis has two basic
modalities: 1) treatment directed against the tumor with radiation
and/or hormone therapy and/or chemotherapy and 2) osteoclast-
suppressive drugs at the bone microenvironment such as using
molecular targeted therapy [23,24]. While these treatments fail to
cure and have undesirable side effects, we have initiated a study to
explore a novel molecular target(s) underling bone remodeling and
focused on osteoblasts, the main cellular component in the bone
microenvironment, and hypothesize that galectin-3 antagonists may
be added to the therapeutic arsenal.
Materials and Methods
Cell Culture and Reagents
An immature pre-osteoblast cell line derived from human fetal
bone, human fetal osteoblast (hFOB), was purchased from
American Type Culture Collection (Manassas, VA) and cultured
at 34°C in standard medium composed of 1:1 mixture of Ham’s
F12 medium and Dulbecco's modified Eagle's medium supple-
mented with 10% FBS following the manufacturer’s protocol. The
third passage cells were used in all experiments. The osteoblastic
differentiation of hFOB cells was induced by 50 μg/ml ascorbic
acid (AA) with 10 mM β-glycerophosphate (β-GP; Sigma-Aldrich,
St Louis, MO) or 100 nM 1α-25-dihydroxycholecalciferol (1,25-
(OH)2D3; ENZO, Farmingdale, NY) [25,26]. The human breast
cancer cell line BT-549 was a gift from Dr Eric W. Thompson (St.
Vincent’s Institute of Medical Research and University of Mel-
bourne, Melbourne, Australia). The human breast cancer cell line
MDA-MB-231 was a gift from Dr Isaiah J. Fidler (University of
Texas MD Anderson Cancer Center, Houston, TX). Human
prostate cancer cell lines LNCaP and PC-3 were purchased from
American Type Culture Collection. Customized polyclonal rabbit
anti–Gal-3 antibody (HL31) was created by Invitrogen (GrandIsland, NY). Rabbit anti-Notch1 polyclonal antibody was purchased
from Abcam (Cambridge, United Kingdom) to detect the cleaved
form of Notch1 named as Notch intracellular domain (NICD). Rabbit
anti-Notch1 polyclonal antibody (H-131) was purchased from Santa
Cruz Biotechnology (Dallas, TX) to detect Notch extracellular domain
(NECD) of full-length Notch1. Mouse anti–β-actin monoclonal
antibody was purchased from Sigma-Aldrich.
Transfection and Plasmid Constructs
The full-length (1-250) galectin-3 DNA fragments were ligated
to p3xFLAG-MYC-CMV-25 expression vector (Sigma-Aldrich)
containing a preprotrypsin leader sequence for secretion. It
was transfected into BT549 and LNCaP cell lines using Lipofecta-
mine LTX and Plus transfection reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. The stable clones
were analyzed using reverse transcription–polymerase chain reaction
(RT-PCR) using the following primer pair: forward, 5′-ATGTCTG
CACTTCTGATCCTAGCTCT-3′; reverse, 5′-CAGATCCT
CTTCTGAGATGAGTTTTT-3′ as described in our previous
study [15]. The secreted protein was collected from serum-free
culture media, and concentrated medium was analyzed by immuno-
blot. Small interfering oligonucleotides targeting human galectin-3
gene (5′-GATCCCGGGAAGAAAGACAGTCGGTTTCAAGA
GAACCGACTGTCTTTCTTCCCTTTTTTGGAAA-3′) and its
complement were synthesized and annealed by Thermo Scientific
(Pittsburgh, PA). It was subcloned into pSilencer 3.1-H1 neo
expression vector (Ambion, Austin, TX) between BamHI and
HindIII sites to construct pSilencer 3.1-H1/siGal3-producing siRNA
targeting galectin-3 mRNA as described in our previous study [27].
PC3 and MDA-MB-231 cells were transfected with this constructed
vector and pSilencer 3.1-H1-negative control vector containing a
random sequence insert using Lipofectamine LTX and Plus reagent
(Invitrogen) according to the manufacturer’s instructions. To confirm
downregulated mRNA expression of galectin-3, the following primers
were used: 5′-GCCACTGATTGTGCCTTA-3′ (forward) and 5′-
AACCGACTGTCTTTCTTCC-3′ (reverse) for human galectin-3
gene, and 5′-TCAACGGATTTGGTCGTATT-3′ (forward) and
5′-TTGGCAGGTTTTTCTAGACG-3′ (reverse) for human
glyceraldehyde-3-phosphate dehydrogenase gene. The secreted protein
was collected from serum-free culturemedia, and concentratedmedium
was analyzed by immunoblot.
Purification of Recombinant Galectin-3
1-250 (full-length, wild-type) and 1-107 and 108-250 (CRD)
human galectin-3 were subcloned into the pET30as (modified
pET30a) vector as a BamHI-XhoI fragment as described in our
previous study [16] and overexpressed in Escherichia coli at 26°C. The
expression construct introduced a His tag to the protein. The soluble
protein was purified by nickel-agarose affinity chromatography. The
protein was concentrated in a buffer containing 20 mMTris (pH 7.9)
and 150 mM NaCl with or without 10 mM DTT. His tags were not
removed from the protein.
Alkaline Phosphatase Assay and Calcium Deposition
The expression of alkaline phosphatase (ALP), an early differen-
tiation marker for osteoblast, was estimated by ALP staining kit
(Biopioneer, San Diego, CA) 7 days after confluence according to
the manufacturer’s instructions. The activity of ALP was measured by
p-nitrophenol phosphate substrate (pNPP; Invitrogen), a substrate for
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days with or without recombinant galectin-3. Briefly, after removing
the culture medium and rinsing with phosphate-buffered saline,
pNPP (1 mg/ml) diluted in buffer containing 0.1 M 2-amino-2-
methyl-1-propanol (pH 10.3) was added and cells were incubated for
30 minutes. Then, the absorbance was determined at 410 nm.
Calcium deposition was detected by Alizarin red S after culturing for
3 weeks. Particle size, particle number, and total area were quantitated
by using ImageJ software.
Quantitative Real-Time PCR
Total RNA was isolated from hFOB cells using RNeasy mini kit
(Qiagen, Valencia, CA); 0.5 μg of total RNA was used for RT
reaction by using RT2 First Strand Kit (Qiagen). Quantitative real-
time PCR was performed using RT2 SYBR Green qPCR master mix
(Qiagen). Values were normalized to glyceraldehyde-3-phosphate
dehydrogenase values as endogenous control. Data are presented as
means + SD.
Immunofluorescence
hFOB cells were fixed with 4% paraformaldehyde, permeabilized
with 0.2% Triton X-100, blocked in 1% BSA/phosphate-buffered
saline, and incubated with anti-Notch1 rabbit antibody as primary
antibody to detect cleaved form of Notch1 (NICD) and then
incubated with TRITC-conjugated secondary antibody. Next, cells
were stained with 4′,6-diamidino-2-phenylindole, washed, and
mounted on a glass slide with SlowFade Light Antifade kit (Molecular
Probes, Eugene, OR). Immunofluorescence images were obtained
using a Zeiss Confocal Laser Microscope LSM 780.
Indirect Co-Culture
hFOB cells were seeded in six-well plates and maintained until
confluence. After confluence, cancer cells were seeded at a density of
5 × 105 cells in cell culture inserts (0.4 μm pore size) in a 1:1 mixture
of Ham's F12 medium and Dulbecco's modified Eagle's medium
containing 10% FBS at 34°C as an indirect co-culture method shown
in Figure 4II-A. Culture medium was changed every 3 days. At 6 days
after co-culture, total RNA of hFOB was extracted by using RNeasy
kit (Qiagen) and subjected to quantitative real-time PCR.
Pull-Down Assay
Purified His-tagged fusion proteins, galectin-3 (1-250), galectin-3
(1-107), and galectin-3 (108-250) were incubated with nickel–
nitrilotriacetic acid (Qiagen) at 4°C for 2 hours with rotation and
washed repeatedly. Next, the beads were incubated at 4°C for 2 hours
with HEK293 cell lysate prepared by cell lysis buffer composed by
40 mM Tris-HCl (pH 7.5), 150 mMNaCl, 0.5% Triton X-100, and
protease inhibitor cocktail, complete EDTA-free (Roche Diagnostics,
Indianapolis, IN). After incubation, the beads were washed repeatedly
and then centrifuged; elution buffer including imidazole and sample
buffer were added to the beads. The protein samples were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
analyzed by immunoblot and Coomassie Brilliant Blue stain.
Luciferase Assay
Following the manufacturer’s protocol, HEK293 cells were seeded
in duplicate at a density of 2.5 × 104 cells per well in 96-well plates
and transfected with RBP-Jk responsive element containing luciferase
reporter construct to monitor Notch signaling activation (Qiagen) byusing Lipofectamine LTX and Plus reagent (Invitrogen). Twenty-four
hours after transfection, cells were stimulated with galectin-3 (1-250)
for another 12 hours. Then, luciferase activities were measured by the
Dual-Luciferase Reporter Assay System (Promega, Madison, WI).
Values were normalized with Renilla luciferase activity under control
of a cytomegalovirus promotor.
Enzyme-Linked Immunosorbent Assay
Conditioned medium from cultured PC-3 cells was used to analyze
the presence of galectin-3 in two replicates by ELISA. The
concentration of galectin-3 secretion was determined using Galec-
tin-3 ELISA kit (BG Medicine, Waltham, MA). For each sample, the
mean of the two replicates was the level of galectin-3.
Statistical Analysis
Statistical differences were determined by analysis of variance or
t test. P b .05 was considered as statistically significant.Results
Galectin-3 Inhibits ALP Expression and Calcium Deposition
in Osteoblast
To test the possible effect of cell-free galectin-3 on the
differentiation of osteoblasts, we employed hFOB, an immature
pre-osteoblast cell line derived from human fetal bone, which has the
potential for spontaneous differentiation after reaching confluence
[25]. In accordance with previous observations, we have verified the
expression of ALP, which is an early differentiation marker for
osteoblasts [28,29] (Figure 1A), and noted that recombinant galectin-
3 inhibited ALP expression under the inducing conditions for
spontaneous differentiation (Figure 1B). To establish which domain
of galectin-3 is involved in this process, lactose (75 mM), a sugar
inhibitor for galectin-3 [30,31], was added to the culture medium,
leading to suppression of the effect of galectin-3 (Figure 1B),
indicating that galectin-3 inhibits osteoblast differentiation through
the CRD. Furthermore, the enzymatic activity of ALP was
investigated by pNPP assay, which was also inhibited by galectin-3
in a dose-dependent manner (Figure 1C). Further, we tested the effect
of galectin-3 on chemically induced differentiation using β-GP with
either AA or 1,25-(OH)2D3 [25,26]. We noted that although the
cells were cultured with these potent osteoblast differentiation
inducers, ALP enzyme activity was independently impaired by
galectin-3 (Figure 1C). These results indicated that galectin-3 is a
suppressor of osteoblast differentiation. Next, we examined whether
the inhibitory effect of galectin-3 on osteoblast differentiation results
from a transcriptional regulation of ALP or post-transcriptional
regulation, such as inhibition of ALP enzyme activity. Quantitative
real-time PCR analysis revealed that the mRNA level of ALP
decreased in response to galectin-3 (Figure 1D), indicating the
regulation of ALP expression at the transcriptional level. Calcium
deposition, a marker for osteoblast differentiation, was detected by
Alizarin Red stain. The number, size of particles, and total area were
all reduced in response to galectin-3 (Figure 1, E and F). Taken
together, these findings demonstrate that galectin-3 impairs the early
differentiation pathway of osteoblasts, consequently resulting in the
inhibition of calcium deposition.
In contrast to recombinant galectin-3, we examined whether
endogenous galectin-3 secreted from cancer cells inhibits osteoblast
differentiation. First, we confirmed the presence of galectin-3 and
Figure 1.Galectin-3 inhibits ALP expression and calcium deposition. (A) Spontaneous ALP expression was identified in hFOB cell line after
reaching confluence. Pink indicates the expression of ALP. 0 DAY or 4 DAY indicate the days after confluence, respectively. (B) Effect of
galectin-3 on inhibition of ALP. Recombinant galectin-3 was added to culture medium in 1.6 μM as final concentration. The suppressive
effect of galectin-3 on osteoblast differentiation was recovered by the treatment of lactose (75 mM), an inhibitor for galectin-3. Sucrose
was used as a control disaccharide. AA with β-GP was used as positive control. (C) Galectin-3 inhibited ALP enzymatic activity in a dose-
dependent manner even if cultured with AA with β-GP or 1,25-(OH)2D3 as inducers for osteoblast differentiation. Black filled circle and
solid line indicate the culture with standard medium for spontaneous differentiation. White open circle and dotted line indicate the culture
with AA and β-GP. Black triangle and dashed and dotted lines indicate the culture with 1,25-(OH)2D3. Data represent means ± SEM.
(D) Galectin-3 suppressed mRNA expression level of ALP. The expression level was determined by quantitative real-time PCR compared
to vehicle control. Data represent means ± SD. (E) Effect of galectin-3 on calcium deposition. The osteoblast differentiation was induced
by 1,25-(OH)2D3. Calcium deposition was detected by Alizarin Red stain at 3 weeks after culture with galectin-3 or vehicle. Recombinant
galectin-3 was added to culture medium every 3 to 4 days. Calcium deposition was selected by using ImageJ software. (F) Galectin-3
inhibited the calcium deposition. Number, size of particles, and total area of the calcium deposition were quantitated. Data represent
means ± SD. *P b .05 versus vehicle control.
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using condition medium containing endogenous galectin-3 secreted
by PC-3 cells, which is derived from bone metastasis lesion of a
patient with prostate cancer. The results showed that cancer-secreted
galectin-3 increased its concentration in a time-dependent manner,
suggesting it could reach to higher concentration (Figure 2A). Next,
to verify the inhibitory effect of galectin-3 on ALP expression,
condition medium containing galectin-3 from cultured PC-3 was
added into the osteoblast cell culture with or without lactose. The
results of ALP stain and measurement of its enzymatic activity
demonstrated that osteoblast differentiation was significantly inhib-
ited by the condition medium containing endogenous galectin-3; it
was recovered by lactose (Figure 2, B and C). Furthermore, to
address the role of cancer-secreted galectin-3 under physiological
status and its concentration, specific galectin-3 antagonist, e.g.,
modified citrus pectin (MCP), was used in indirect co-culture
experiment with osteoblast cells. The results showed that ALP
expression was inhibited by co-cultured PC-3 cells, and it was
recovered by MCP. These results suggested that inhibitory effect of
secretory factors from PC-3 cells on osteoblast differentiation is
mediated by galectin-3 (Figure 2, D and E). Taken together, thesefindings showed that the results of recombinant galectin-3 (Figure 1)
are similar to those of secreted endogenous galectin-3 (Figure 2).
Galectin-3 Inhibits Osteoblast Differentiation
Galectin-3 inhibits osteoblast differentiation at the transcriptional
level of ALP (Figure 1D). We examined whether it also inhibits other
differentiation markers, i.e., COL1A1, IBSP, and BGLAP, and
transcriptional factors that were reported to regulate the osteoblast
differentiation, i.e., RUNX2 and SP7 [6,28,29]. RUNX2 is an
essential transcription factor for osteoblast differentiation, which leads
to the promoter activation of COL1A1, ALPL, IBSP, BGLAP, or
more [32]. SP7, known as osterix, functions downstream of RUNX2
and it also regulates the major osteoblast differentiation markers, i.e.,
COL1A1, ALPL, IBSP, and BGLAP [33,34]. COL1A1 is known as
type I collagen and an early marker of osteoblast differentiation
because it is a primary product of osteoblast during bone formation
[28,29]. IBSP is known as bone sialoprotein, an intermediate stage
marker [28,29]. BGLAP, known as osteocalcin, is expressed in
matured osteoblast and therefore is currently considered as the
specific marker for late differentiation stage [28,29]. Quantitative
real-time PCR analysis demonstrated that the transcriptional levels of
Figure 2. Endogenous galectin-3 inhibits ALP expression. (A) Cancer-secreted galectin-3 accumulated in condition medium in a time-
dependent manner. PC-3 cells were cultured with condition medium for 0 to 2 days, and then it was subjected to immunoblot and ELISA
without concentration. (B and C) Secretory factor by PC-3 cells inhibits ALP expression and its enzymatic activity in a sugar-dependent
manner. Condition medium from PC-3 cell culture was concentrated to 20-fold, and 5 μl of concentrated medium was added into
osteoblast cell culture in a 96-well plate. Culture mediumwas changed every 3 days. After 1 week, it was subjected to ALP stain and pNPP
assay. The suppressive effect of cancer-secretory factor on osteoblast differentiation was recovered by the treatment of lactose (75 mM).
(D and E) Inhibitory effect of secretory factors from PC-3 cells on osteoblast differentiation is mediated by galectin-3. Osteoblast cells
were subjected to ALP stain and pNPP assay after co-culture with PC-3 cells for 1 week. MCP, a specific inhibitor of galectin-3, recovered
the downregulated ALP expression and its activity. Data represent means ± SD. *P b .05 versus vehicle control.
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(Figure 3), indicating that galectin-3 maintained osteoblasts in an
undifferentiated state. These results imply that galectin-3 is a potent
osteoblast differentiation inhibitor.
Cancer Cell Galectin-3 Inhibits Osteoblast Differentiation
The results described above documented that recombinant
galectin-3 inhibited osteoblast differentiation, and since it may be
argued that it may have a different three-dimensional conformation or
affinity to endogenous galectin-3, we next tested whether galectin-3
secreted by cancer cells affect osteoblast differentiation. Galectin-3 is
secreted from tumor cells by a non-conventional secretory pathway
[35]. Thus, PC-3 and LNCaP prostate cancer cell lines and MDA-
MB-231 and BT-549 breast cancer cell lines were used in a co-culture
experiment. PC-3 is derived from a bone metastatic site in patients
with prostate cancer and causes osteolytic lesions [36]. Both
intracellular and secreted galectin-3 were detectable in PC-3 cells
and culture medium (Figure 4I-A). MDA-MB-231 also has high
metastatic potential to bone in an intra-cardiac injection model and
causes osteolytic lesions [4], and the cells both expressed endogenousgalectin-3 and secreted it (Figure 4I-A). LNCaP and BT-549 cells
were devoid of galectin-3 (Figure 4I-A) and were transfected with
p3xflag-myc-cmv-25 plasmid containing the preprotrypsin leader
sequence as a secretory signal peptide for secretion of expressed
protein into the culture medium. Transfection was confirmed by RT-
PCR and identification of galectin-3 in culture medium by
immunoblot. It was observed that indeed the transfected cell lines
express and secrete galectin-3 (Figure 4, I-B and C). Moreover,
galectin-3 downregulated PC-3 and MDA-MB-231 lines were
established by using sh-RNA. Decreased expression was confirmed
by RT-PCR and immunoblot for intracellular expression and secretion
(data not shown). These established cell lines were subjected to a co-
culture experiment with hFOB human osteoblasts (Figure 4II-A).
In the sample of hFOB co-cultured with LNCaP and BT-549 cells
transfected with plasmid containing galectin-3, RUNX2, SP7,
COL1A1, ALPL, IBSP, and BGLAP were decreased compared to
control vector clone (Figure 4, II-B and C) as determined by
quantitative real-time PCR. However, in the sample of co-culture
with downregulated galectin-3, PC-3 and MDA-MB-231, SP7, and
ALPL expression levels were increased compared to scrambled vector
Figure 3. Galectin-3 inhibits the gene expressions for osteoblast differentiation. RNA samples were extracted at 1 week after the addition
of recombinant galectin-3 with inducers for osteoblast differentiation. mRNA levels were determined by quantitative real-time PCR.
Results are presented as fold changes compared to the sample before confluence. Data represent means ± SD. White bars, culture with
vehicle control. Black bars, with galectin-3. *P b .05 versus vehicle control.
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with recombinant galectin-3 and support the conclusion that
galectin-3 secreted by cancer cells inhibits osteoblast differentiation.
Galectin-3 Inhibits Osteoblast Differentiation through Notch
Signaling
Osteoblast differentiation is regulated by various pathways such as
Hedgehog, Wnt, bone morphogenetic protein (BMP), FGF signaling,
and Notch signaling [6]. Wnt, BMP, and FGF signal pathways were
reported to positively regulate osteoblast differentiation. In contrast,
Notch signaling pathway inhibits osteoblast differentiation [37–42].
Since the results depicted here show that galectin-3 suppresses
osteoblast differentiation (Figures 1–4), it was necessary to examine
the possible relationship between galectin-3 and Notch signaling
pathway. To address thus, we testedHEY-1 expression, a target gene of
Notch signaling in osteoblasts [41,42]. HEY-1 was upregulated by theaddition of recombinant galectin-3 to the cell cultures (Figure 5A).
Consistently, co-culture with BT-549 transfected with galectin-3
plasmid upregulated HEY-1 expression (Figure 5B), suggesting that
the osteoblast differentiation inhibitory effect of galectin-3 is
mediated by Notch signaling. Previous reports suggested that
Notch1 impairs osteoblast differentiation through NICD, a cleavage
form of Notch1 [37,38]. NICD releases from cell membranes and
translocates into the nucleus to activate the target genes after the
binding with ligands [6,43,44]. Therefore, we next tested whether
NICD induction is affected by galectin-3. Immunoblot analysis
showed that galectin-3 strongly induced NICD expression in a time-
dependent manner in hFOB cells (Figure 5C). However, full-length
Notch1 was not affected (Figure 5C). Interestingly, galectin-3–
induced NICD was inhibited by lactose (Figure 5D) and antibodies
against galectin-3 (Figure 5E). Moreover, immunofluorescence
analysis has confirmed that galectin-3 induces NICD in the
Figure 4. Cancer-secreted galectin-3 inhibits the gene expression for osteoblast differentiation. (I) Established clones for co-culture
experiment. (A) Comparison of galectin-3 expression in cell lysate and secreted galectin-3 between bone metastatic cancer and non-bone
metastatic cancer cell line. (B) LNCaP transfected p3xflag-myc-cmv-25. LNCaP clone 14-3 had potential to secrete galectin-3 by
transfection of p3xflag-myc-cmv-25 inserted full-length galectin-3 sequence (1-250). (C) BT-549 transfected p3xflag-myc-cmv-25. BT-549
clone 6-1 had potential to secrete galectin-3 by transfection of p3xflag-myc-cmv-25 inserted full-length galectin-3 sequence (1-250).
(II) Cancer-secreted galectin-3 inhibits osteoblast differentiation in a co-culture experiment. (A) Schematic representation of indirect co-
culture using cell culture inserts. Osteoblast cells were cultured in a six-well plate until confluence, and after that, cancer cells were
seeded on the inserts. On 6 days after co-culture with cancer cells, RNA samples of hFOB cells were extracted and expression levels were
determined by quantitative real-time PCR. Results are presented as fold change compared to empty vector cells. (B) Results of co-culture
with LNCaP. mRNA levels of osteoblast differentiation marker were compared between co-culture with empty vector cells and galectin-3
secretable cells, clone 14-3. White bars, co-culture with empty vector cells. Black bars, co-culture with galectin-3 transfected stable clone
14-3. (C) Results of co-culture with BT-549. mRNA levels of osteoblast differentiation marker were compared between co-culture with
empty vector cells and galectin-3 secretable cells, clone 6-1. White bars, co-culture with empty vector clone. Black bars, co-culture with
galectin-3 transfected stable clone 6-1. Data represent means ± SD. *P b .05 versus empty vector cells.
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results suggested that the inhibitory effect of galectin-3 on osteoblast
differentiation is mediated by Notch signaling.
Galectin-3 Induction of Notch Signaling Is Carbohydrate
Dependent
Next, to delineate the underlying mechanism whereby galectin-3
enhances Notch signaling pathways, we examined the effect of
galectin-3 on Notch signaling in HEK293 cells treated with the
deletion mutants of galectin-3. Our previous results showed that the
CRD plays a crucial role for inhibition of osteoblast differentiation(Figures 1D and 6B). Therefore, we purified the CRD of galectin-3
(108-250) and domain 1-107 by using the same plasmid (pET30) as
full-length galectin-3 (1-250) to compare the potential of galectin-3
for induction of Notch signaling (Figure 6A). In HEK293, full-length
galectin-3 (1-250) induced NICD in a time-dependent manner. The
CRD of galectin-3 (108-250) also increased NICD, whereas other
portion of galectin-3 (1-107) did not (Figure 6B). In addition,
according to the results of a pull-down assay, full-length (1-250) and
carbohydrate recognition domain (108-250) of galectin-3 bound
Notch1, whereas galectin-3 (1-107) did not (Figure 6C). Lastly, we
have monitored the activity of Notch signal transduction pathway
Figure 5. Galectin-3 upregulates HEY-1 and induces NICD in hFOB cells. (A) Recombinant galectin-3 induced mRNA expression level of HEY-1. RNA samples were extracted at 1
week after addition of recombinant galectin-3 (1.6 μM) with or without inducers for osteoblast differentiation. mRNA level was determined by quantitative real-time PCR. Results are
presented as fold changes compared to the vehicle control. White bars, culture with vehicle control. Black bars, with galectin-3. (B) Cancer-secreted galectin-3 induced mRNA
expression level of HEY-1 in co-culture experiment. RNA samples were extracted at 6 days after co-culture with transfected cancer clones with or without secretion of galectin-3.
Results are presented as fold changes compared to the empty vector cells. Data represent means ± SD. White bars, co-culture with empty vector cells. Black bars, co-culture with
galectin-3 transfected stable clone. EV, empty vector cells. *P b .05 versus vehicle or empty vector cells. (C) Galectin-3 induced NICD in hFOB cells in a time-dependent manner.
Recombinant galectin-3 was added to culture medium in 1.6 μM as final concentration, respectively. (D) Suppression study using lactose; 75 mM of lactose or sucrose was used as
final concentration. Cell lysates were extracted 12 hours after treatment. (E) Suppression study using HL31 anti–galectin-3 rabbit polyclonal antibody; 15 μg/ml HL31 was used as
final concentration. Cell lysates were extracted 12 hours after treatment. The same concentration of rabbit isotype IgG was used as control (data were not shown).
(F) Immunofluorescence images of hFOB with or without galectin-3 stimulation. Recombinant galectin-3 was added to culture medium in 1.6 μM as final concentration. Cells were
fixed 24 hours after treatment. Images were shown for NICD (TRITC, red) and 4′,6-diamidino-2-phenylindole (nuclear stain, blue). White bar indicates 10 μm as scale.
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Figure 6. Full-length galectin-3 induces Notch signaling in HEK293 cells. (A) Schematic representation of deletion mutants of galectin-3
and its illustration. (B) Galectin-3 induced NICD in HEK293 cells in a time-dependent manner. Recombinant galectin-3 was added to
culture medium in 1.6 μM as final concentration. (C) Result of pull-down assay. Full-length galectin-3 (1-250) and the CRD of galectin-3
(108-250) bound Notch1, whereas other portion of galectin-3 (1-107) did not bind. Total cell lysate of HEK293 was used as input sample.
Coomassie stain was used to show the presence of recombinant galectin-3 in each sample. (D) Results of luciferase assay. HEK293 cells
were transfected with the luciferase reporter construct containing RBP-Jk transcriptional response element to monitor the Notch
signaling activation. Then, HEK293 cells were treated with recombinant full-length galectin-3 (1-250). Data represent means ± SD.
Neoplasia Vol. 16, No. 11, 2014 Galectin-3 inhibits osteoblast differentiation Nakajima et al. 947using HEK293 cells with luciferase reporter containing responsive
element to Notch activation and noted that full-length galectin-3
induces Notch signaling, and this induction was mediated by the
CRD (Figure 6D).
Discussion
Here, we presented a novel view of the inhibition of osteoblast
differentiation by cancer-secreted galectin-3, not previously de-
scribed. We report that following galectin-3–Notch1 interaction
results in the appearance of NICD leading to up-regulation of HEY-1
and down-regulation of SP7 and RUNX2 expression. These
expression changes manifested themselves in the inhibition of
osteoblast differentiation. To date, it is widely accepted that, in the
bone, Notch signaling mediates the communication between
neighboring cells by direct cell-cell contact of membrane-associated
jagged-1, 2 and delta like-1, 3, 4 [6,43–45]. The data presented here
reiterate this central role of Notch signaling and that its induction by a
secretory factor, e.g., galectin-3, suppresses osteoblast differentiation.
Because patients with breast and prostate cancer metastases have ahigher serum concentration of circulated galectin-3 [13,14], we
explored its putative role in bone metastasis lesions. The results
showed that galectin-3 inhibits osteoblast differentiation, it was
apparent from the co-culturing experiments with LNCaP and BT-
549 expressing galectin-3 following their transfection with human
galectin-3 cDNAwith a secretory leader peptide (Figure 4, II-B and C).
Furthermore, the results indicated that SP7 and ALPL are the
main galectin-3 differentiation suppression targets of downstream
of Notch signaling. Similarly to galectin-3, previous studies have
indicated that tumor necrosis factor-alpha (TNF-α), epidermal growth
factor, sclerostin, and Dickkopf1 can impair osteoblast differentiation
[46–50]. Bone metastasis is clinically classified into three types:
osteolytic, osteoblastic, andmixed lesions [51]. Bone remodeling results
from the activation statuses of osteoblasts and osteoclasts or the
summation of secretory/non-secretory factors derived from cellular
components of the bone microenvironment, bone matrix, and
cancer; we thus speculate that the potent function of tumor-
associated galectin-3 on osteoblasts should be considered as a new
therapeutic target for patients with osteolytic bone metastasis.
Figure 7. Proposed model for the regulation of Notch signaling by
cancer-secreted galectin-3. Bone metastatic cancer cells secrete
galectin-3 in the bonemicroenvironment. Secreted galectin-3 binds
to Notch1 through the CRD. After the interaction, NICD translo-
cates to the nucleus, and consequently, it upregulates Notch target
genes such as HEY-1. These events suppress osteoblast differen-
tiation and cause bone remodeling in bone metastatic lesions.
948 Galectin-3 inhibits osteoblast differentiation Nakajima et al. Neoplasia Vol. 16, No. 11, 2014Activation of Notch signaling in the bone microenvironment of
metastatic lesions plays a critical role in the promotion of bone
metastasis through tumor-derived jagged-1, a Notch ligand [21].
Although Notch signaling is thought to be activated by cell-to-cell
contact, our data suggest an additional function whereby cancer-
secreted galectin-3 directly induces Notch signaling activation leading
to the inhibition of osteoblast differentiation. Mammals possess four
different Notch transmembrane receptors, referred to as Notch 1-4.
Among them, Notch1 is most important for osteoblast differentiation
[37,38,52]. After binding their ligands, Notch receptors undergo a
proteolytic cleavage that is catalyzed by the γ-secretase complex. As a
result, NICD is released from the plasma membrane and translocates
to the nucleus and activates the transcription of target gene HEY-1,
which in turn controls the expression of RUNX2 and SP7 as crucial
transcriptional factors for osteoblast differentiation [6,43,45]. In this
study, we confirmed the above and showed that galectin-3 also
induces the appearance of NICD following galectin-3–Notch
interaction in hFOB cells (Figures 3–5). The extracellular domain
of Notch1 contains 36 tandem epidermal growth factor-like repeats,
many of which are modified with O-fucose (6-deoxy-galactose) [53],
and O-fucose glycan plays an important role in ligand-mediated
Notch activation and embryogenesis [54,55]. Furthermore, the
presence of galactose on O-fucose glycans differentially affects the
intensity of Notch signaling [56], clarifying the sugar-dependent
Notch–galectin-3 binding (Figure 6).
Our study depicts a new molecular mechanism in which inhibition
of osteoblast differentiation by cancer-secreted galectin-3 may lead to
bone destruction. In conclusion, we hypothesize that galectin-3
secreted by tumor cells growing in bone inhibits osteoblast
differentiation through Notch signaling (Figure 7), and therefore, itis necessary to consider galectin-3 expression during treatment, which
make this study highly significant.References
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